Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors

(2019) Lorenzo Gervaso et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

(2019) George W. Sledge et al.   JAMA Oncology

Overcoming endocrine resistance in hormone receptor–positive breast cancer

(2018) A. AlFakeeh et al.   Current Oncology

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

The association of early toxicity and outcomes for patients treated with abemaciclib.

(2018) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate

(2018) Jill C. Chappell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

(2017) Loay Kassem et al.   Breast Cancer

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation

(2015) A-S Tigan et al.   ONCOGENE

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments

(2014) Claudia Omarini et al.   BREAST CANCER RESEARCH AND TREATMENT

Endocrine Therapy of Breast Cancer

(2011) F. Lumachi et al.   CURRENT MEDICINAL CHEMISTRY